The Proposed PASI-HD Provides More Precise Assessment of …
WEBJul 8, 2021 · We describe a modification to the PASI, termed PASI-high discrimination (PASI-HD), for determination of more accurate psoriasis severity in body regions where < 10% of the body surface area is affected. The methodology for assessing disease severity in these conditions is described.
27876 The PASI-HD improved precision in measuring disease …
WEBPASI-HD was developed to obtain higher discrimination in low BSA using the actual percentage of involvement of each anatomical area. PASI and PASI-HD were assessed in a randomized, vehicle-controlled, phase 2b, 12-week study of once-daily roflumilast cream.
Disease Assessment in Psoriasis - PMC - National Center for ...
WEBThe proposed PASI-HD provides more precise assessment of plaque psoriasis severity in anatomical regions with a low area score. Dermatol Ther (Heidelb) 2021; 11 :1079–83. [ PMC free article ] [ PubMed ] [ Google Scholar ]
42828 Efficacy and safety of roflumilast cream 0.3% in patients …
WEBThe Psoriasis Area and Severity Index (PASI) and a modified version that allows higher discrimination (PASI-HD) in which area scores for <10% of an anatomical region are 0.1-0.9 rather than default to 1 were evaluated.
WEBthis commentary is to introduce the PASI-high discrimination (PASI-HD), a measure designed to be used in clinical trials to provide greater precision in estimating disease severity and evaluate treatment effectiveness. PASI-HD remains true to the PASI measure by maintain-ing the anatomical regions of the PASI. PASI-HD
WEBPASI-HD is a new assessment developed to more precisely measure severity of psoriasis patients in regions where the area of involvement is <10%. Psoriasis Area and Severity Index (PASI) is a gold standard measure in psoriasis clinical trials but lacks sensitivity in affected areas <10%.
Advancing Innovative Therapies For Mild-To-Moderate Psoriasis …
WEBMay 8, 2023 · PASI-HD empowers physicians and patients with accurate and quantitative data. For example, when a patient comes in for a visit, I can tell them what their PASI-HD score is on that day, what it was at their last visit, and clearly define if their condition is the same, improving, or worsening.
Arcutis Advances Science of Psoriasis Drug Development with …
WEBJul 21, 2021 · The new method, PASI-high discrimination (PASI-HD), is designed to be used in clinical trials among patients for whom the areas of affected body surface within the anatomical regions measured by PASI are less than 10 percent.
PASI-HD: Modification to PsO Severity Scale Aims at Mild-to …
WEBJul 21, 2021 · PASI-high discrimination (PASI-HD), designed to be used in clinical trials among patients for whom the areas of affected body surface are less than 10 percent, was developed by Arcutis Biotherapeutics, Inc. in conjunction with leading psoriasis experts.
The Proposed PASI-HD Provides More Precise Assessment of …
WEBJul 8, 2021 · The Proposed PASI-HD Provides More Precise Assessment of Plaque Psoriasis Severity in Anatomical Regions with a Low Area Score.
- Some results have been removed
Skip to content